Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
NCT01302834 · View on ClinicalTrials.gov ↗
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether radiation therapy is more effective with cisplatin or cetuximab in treating oropharyngeal cancer. PURPOSE: This phase III trial is studying radiation therapy with cisplatin or cetuximab to see how well it works in treating patients with oropharyngeal cancer.
Conditions Studied
Interventions
- DRUG cisplatin
- RADIATION IMRT
- BIOLOGICAL cetuximab
Study Locations (20)
California
- Auburn Radiation Oncology — Auburn
- Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center — Burbank
- Radiation Oncology Centers - Cameron Park — Cameron Park
- Mercy Cancer Center at Mercy San Juan Medical Center — Carmichael
- Enloe Cancer Center at Enloe Medical Center — Chico
- City of Hope Comprehensive Cancer Center — Duarte
- Rebecca and John Moores UCSD Cancer Center — La Jolla
- Kaiser Permanente - Division of Research - Oakland — Oakland
- Rohnert Park Cancer Center — Rohnert Park
- Radiation Oncology Center - Roseville — Roseville
- Radiological Associates of Sacramento Medical Group, Incorporated — Sacramento
- Mercy General Hospital — Sacramento
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco
- — Santa Clara
- Kaiser Permanente Medical Center - South San Francisco — South San Francisco
- Solano Radiation Oncology Center — Vacaville
Colorado
- Rocky Mountain Cancer Centers - Aurora — Aurora
- Boulder Community Hospital — Boulder
- Penrose Cancer Center at Penrose Hospital — Colorado Springs
Alaska
- Providence Cancer Center — Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 987 participants |
| Start Date | 2011-06 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01302834
The ClinicalTrials.gov registry entry for NCT01302834 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 987 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 37 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 3 interventions — of which cisplatin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01302834 reports 20 study locations spanning 3 distinct geographic areas — top geographies include California, Colorado, Alaska. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01302834 about?
NCT01302834 is a clinical study titled "Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab...
What is the current status of trial NCT01302834?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 987 participants. The study started on 2011-06. Estimated completion is 2025-09-04.
What conditions does trial NCT01302834 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Precancerous Condition. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT01302834?
The interventions under investigation include: cisplatin (DRUG), IMRT (RADIATION), cetuximab (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT01302834?
This trial is sponsored by Radiation Therapy Oncology Group, which has 37 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01302834 being conducted?
This trial has 20 study locations across Alaska, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.